TAG:
specialty lab
“October 7, 2002 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume IX No. 14 – October 7, 2002 Issue
Without much fanfare or notice, Liposcience Inc. of Raleigh, North Carolina tested the waters for an initial public offering (IPO) last month. It found market conditions unfavorable for its proposed offering of $92 million and deferred its IPO. Liposcience, with annual revenues of $1…
Esoterix Ready to Launch National Marketing Blitz
By Robert Michel | From the Volume IX No. 13 – September 16, 2002 Issue
CEO SUMMARY: It was 1995 when several specialty testing lab companies were acquired by a new company called Esoterix. Immediately the lab industry viewed Esoterix as a “put-together” lab company. However, since 2000, executives at Esoterix have invested $50 million to integrate operat…
Non-Pathologists Altering U.S. Laboratory Industry
By Robert Michel | From the Volume IX No. 13 – September 16, 2002 Issue
CEO SUMMARY: It’s an interesting contradiction. On one hand, most pathologists enthusiastically recognize the value that diagnostic testing services provide to the healthcare community. On the other hand, too often it is non-laboratorians who provide the investment capital and entrepren…
Changes Expected in Market For Hospital Reference Testing
By Robert Michel | From the Volume IX No. 13 – September 16, 2002 Issue
CEO SUMMARY: For the hospital send-out testing marketplace, 2002 has been an eventful year. First came the acquisition of American Medical Laboratories by Quest Diagnostics Incorporated. In April, Specialty Laboratories disclosed its problems with state and federal laboratory regulators. …
Specialty Laboratories’ New CEO Reveals How His Company Is Changing
By Robert Michel | From the Volume IX No. 11 – August 5, 2002 Issue
“You will see a more tightly focused Specialty Labs. We won’t try and do everything, rather we will do what is important for our customers.” —Douglas S. Harrington, M.D CEO SUMMARY: In recent months, several events roiled the market for hos…
Unfolding Events at Unilab, Specialty Labs and Dynacare
By Robert Michel | From the Volume IX No. 11 – August 5, 2002 Issue
RECENT WEEKS BROUGHT important developments to several public lab companies. Each development changes and alters the competitive marketplace for laboratory testing services. It was big news at Specialty Laboratories, Inc. when the troubled lab company signed a Plan of Correction (PO…
Specialty Progresses With CA Lab Regulators
By Robert Michel | From the Volume IX No. 10 – July 15, 2002 Issue
CEO SUMMARY: Earlier this month California laboratory regulators found Specialty Laboratories, Inc. to be “in substantial compliance with California clinical laboratory law.” This is an important milestone in restoring the lab company to full compliance with both state and federal labor…
United Kingdom Soon to Tackle Consolidation of Hospital Labs
By Robert Michel | From the Volume IX No. 10 – July 15, 2002 Issue
CEO SUMMARY: Consolidation and regionalization of hospital laboratory testing are not isolated phenomenons. Beginning in the late 1980s, individual provinces in Canada began to rationalize lab testing services by building core labs and consolidating lab services across multiple hospitals….
Specialty Lab’s Woes Trigger Big Market Shift
By R. Lewis Dark | From the Volume IX No. 9 – June 24, 2002 Issue
IT’S THE UNPUBLICIZED STORY BEHIND THE STORY. Most of the laboratory industry knows that Specialty Laboratories, Inc. is the target of sanctions issued by both federal and state laboratory regulators. But the impact of this development has yet to be recognized across the industry. …
Specialty Labs Struggles To Maintain Operations
By Robert Michel | From the Volume IX No. 9 – June 24, 2002 Issue
CEO SUMMARY: In April, Specialty Laboratories, Inc. disclosed that state and federal regulators had placed sanctions on the esoteric testing company, including revocation of its CLIA-88 license, subject to legal appeal. One main source of concern is the fact that, over the past 10 weeks, …
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized